Samsung Biologics has introduced two new platforms focused on optimized antibody production and systematic screening of molecules at an early development stage.
AffaMed Therapeutics has announced that the US FDA has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor...
Wheeler Bio, a newly established company aiming accelerate the translation of therapeutic innovation into clinical impact, recently closed a US$14m seed financing round.
ATMPS Ltd, a UK developer of blockchain-based cell orchestration platforms for advanced therapies is collaborating with US quality and compliance consultancy, Assurea LLC, to develop a fully complaint blockchain approach for end-to-end supply chain management...